Find clarity in assessing cancer risk
Get the clarity you need to stratify risk for each of your high-risk unaffected patients accurately. Genetic testing helps you determine personalized cancer risk management options based on unique genetic features for each patient you treat – and increases their odds for a healthy future.
The MyRisk® Hereditary Cancer Test with RiskScore® helps you get the clarity you need to determine the best risk management options for your patient in 14 days or less. The multi-gene panel analyzes the risk for 11 cancers to estimate a patient’s 5-year and lifetime risk for developing breast cancer.
Request more information and explore ordering options
Who is MyRisk for?
MyRisk is designed for surgeons treating patients diagnosed with or at risk for:
- Breast cancer*
- Ovarian cancer
- Prostate cancer
- Pancreatic cancer*
- Uterine cancer
- Colorectal cancer
- Skin cancer
- Gastric cancer
- Renal cancer
- Lung cancer
- Endocrine cancer
Whether you’re a community-based surgeon or part of an acute hospital setting, MyRisk offers the comprehensive genetic insights you need to make informed decisions that can improve patient outcomes and provide peace of mind.
*eligible for MyRisk STAT
Take the next step with MyRisk
Get started by downloading the provider guide to learn more.
Why choose MyRisk?
Lowest
BRCA1/2 VUS rates
With MyRisk, leverage the industry’s lowest BRCA1/2 VUS rates for clarity in treatment decisions.1
Double
Amount of mutations detected
Panel testing can detect nearly double the amount of mutations compared to single gene testing.2
53%
MyRisk helps patients qualify
53% of patients tested with MyRisk qualify for a change in their medical management vs. approximately 10% expected if tested with other labs.3
Testing process made easy
Myriad provides easy-to-use resources that can seamlessly integrate genetic testing into your practice.
1. Patient identification
OPTIONS
- Digital screening with MyGeneHistory™
- Radiology Information Systems
- Mammography Information Systems
2. Pre-test education
(with board-certified genetic counselor)
INCLUDES
- Individualized education (on-demand)
- Follow-up documentation (pre-populated test request form, three-generation pedigree, chart notes)
3. Ordering
OPTIONS
- Online portal
- Virtual/paper orders
- EMR integrations
- Phlebotomy support
- Technical/ordering support
4. Affordability
INCLUDES
- Personalized cost estimates
- 9/10 Patients pay $0 ($54 average)
- Financial assistance and payment plans available
5. Results
INCLUDES
- Personalized Tyrer-Cuzick/RiskScore with a 5-year and lifetime risk (when applicable)
- Online portal or results by mail
- EMR integration
- Medical management tool included
6. Post-test discussions
(with board-certified genetic counselor)
INCLUDES
- Individualized discussion of results (on‑demand or scheduled)
- Detailed summary of notes
Testing process made easy
Myriad provides easy-to-use resources that can seamlessly integrate genetic testing into your practice.
MyRisk hereditary cancer 48 gene panel
| Genes | Breast | Ovarian | Colorectal | Uterine | Skin | Pancreatic | Gastric | Prostate | Renal | Lung | Endocrine | Other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BRCA1 |
|
|
|
|
||||||||
| BRCA2 |
|
|
|
|
|
|||||||
| MLH1 |
|
|
|
|
|
|
|
|
||||
| MSH2 |
|
|
|
|
|
|
|
|
||||
| MSH6 |
|
|
|
|
|
|
|
|
||||
| PMS2 |
|
|
|
|
|
|
|
|
||||
| EPCAM |
|
|
|
|
|
|
|
|
||||
| CTNNA1 |
|
|||||||||||
| APC |
|
|
|
|
||||||||
| MUTYH Monoallelic | ||||||||||||
| MUTYH Biallelic |
|
|
||||||||||
| CDKN2A (p16INK4a) |
|
|
||||||||||
| CDKN2A (p14ARF) |
|
|
||||||||||
| CDK4 |
|
|
||||||||||
| TP53 |
|
|
|
|
|
|
|
|
|
|||
| PTEN |
|
|
|
|
|
|
|
|||||
| STK11 |
|
|
|
|
|
|
|
|
||||
| CDH1 |
|
|
||||||||||
| PALB2 |
|
|
|
|||||||||
| ATM |
|
|
|
|||||||||
| CHEK2 |
|
|
||||||||||
| CHEK2 Biallelic |
|
|
||||||||||
| RAD51C |
|
|
||||||||||
| RAD51D |
|
|
||||||||||
| BARD1 |
|
|||||||||||
| BRIP1 |
|
|||||||||||
| BMPR1A |
|
|
|
|||||||||
| SMAD4 |
|
|
|
|||||||||
| VHL |
|
|
|
|||||||||
| RET |
|
|
||||||||||
| MEN1 |
|
|
||||||||||
| BAP1 |
|
|
|
|||||||||
| TSC1 |
|
|
||||||||||
| TSC2 |
|
|
||||||||||
| FH |
|
|
|
|||||||||
| FLCN |
|
|
|
|||||||||
| TERT |
|
|||||||||||
| MITF |
|
|||||||||||
| MET |
|
|||||||||||
| SDHA |
|
|
|
|||||||||
| SDHB |
|
|
|
|||||||||
| SDHC |
|
|
|
|||||||||
| SDHD |
|
|
|
|||||||||
| POLD1 |
|
|||||||||||
| POLE |
|
|||||||||||
| GREM1 |
|
|||||||||||
| AXIN2 |
|
|||||||||||
| NTHL1 Monoallelic | ||||||||||||
| NTHL1 Biallelic |
|
|
|
|
||||||||
| MSH3 Monoallelic | ||||||||||||
| MSH3 Biallelic |
|
|||||||||||
| HOXB13 |
|
|||||||||||
| EGFR |
|
MyRisk testing provides you with clear results you can trust
Most hereditary cancer tests only produce positive or negative results. MyRisk takes this a step further, including the MyRisk Management Tool in every report. This easy-to-use guide breaks down everything you need to know about using these results to inform your patient’s personal care plan today and in the future.
Hear from patients whose lives have been transformed
“I’ve had a dozen overnight hospitalizations, the removal of multiple body parts, you know, really trying times emotionally and physically. And it is such a gift to me that I feel like I took one for the team so my kids don’t have to go through that. They get to know what their odds are and they get to do something about it.”
Katya Lezin
Our research studies
Take the first step towards more informed, personalized cancer care for your patients.
References:
- Mundt E, et al. Driving Down the Rate of Variants of Uncertain Significance as the Myriad MyRisk® Multigene Panel Grows [White paper]. Myriad Genetics. Oct 2019.
- Yorczyk A, et al. Use of panel tests in place of single gene tesets in the cancer genetics clinic. Clin Genet. 2015 Sep;88(3):278-282.
- Myriad internal data based on MyRisk tests reported between 9/1/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.
